Xenon Pharmaceuticals price to sales ratio XENE

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not in our data today
Last meaningful: 184×; Feb 2023
10-year median: 63.7×
10-year range: 12.5× to 188×
Peer median: 3.5×

Xenon Pharmaceuticals has no meaningful price to sales ratio today: it is not in our data for Oct 23, 2026.

It was last meaningful in Feb 2023, at 184×.

On the days it had one over the last ten years, its median was 63.7×, from 12.5× in Oct 2020 to 188× in Feb 2023.

Price to sales ratio over time

median 63.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	184×	172×	188×
2022	187×	63.9×	187×
2021	81.2×	16.6×	81.8×
2020	17.7×	12.5×	17.7×
2019	n/m a value too high to mean anything
2018	118×	75.1×	118×
2017	75.9×	29.8×	83.1×
2016	29.6×	6.2×	31.7×
2015	4.9×	4.9×	9.3×

Against its peers

Companies in Drug Manufacturers - General nearest Xenon Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
XENEXenon Pharmaceuticals	n/m
OGNOrganon	0.6×
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
INDVIndivior Pharmaceuticals	3.1×
NRIXNurix Therapeutics	3.9×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
Peer median	3.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Xenon Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.